Inherited Cardiac cONditions In Kids

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

300 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-09-01

Study Completion Date

2026-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

All patients with heart disease should have the opportunity to participate in research into their condition, to advance knowledge and treatment. The investigators have built an online registry and database - The Heart Hive - to connect research-willing participants (with heart muscle disease) with active researchers and projects. Participants enrol and upload their own data through the website.This study uses The Heart Hive platform to study cardiomyopathies - heart muscle disease. These are progressive diseases, and there is a need to better understand what factors affect the chances of developing cardiomyopathy, and how the condition progresses. The study will collect information about participants diagnosis, DNA for genetic analysis, and then follow participants' clinical progress. The study will identify genetic variants that cause cardiomyopathy, and determine which specific genetic or environmental factors predict disease severity, progression and response to treatment, with an overall objective of identifying new and personalised treatments for patients with this disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Families' Experiences of Paediatric ICC Diagnosis

NCT02737111

Inherited Cardiac Conditions

UNKNOWN NA

Heart Failure in Adult Patients With a History of Congenital Heart Disease

NCT00208754

Congenital Heart Defects

TERMINATED

Critical Congenital Heart Defect (CHD) Outcomes in Children

NCT00208689

Congenital Heart Disease

TERMINATED

Genetics of Congenital Heart Disease

NCT01192048

Congenital Heart Disease

RECRUITING

National Collaborative to Improve Care of Children With Complex Congenital Heart Disease

NCT02852031

Hypoplastic Left Heart Syndrome (HLHS)

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a multi-centre, observational study of children with rare inherited cardiac conditions. The focus of the study will be on children with clinically diagnosed cardiomyopathy and their unaffected parents, with collection of baseline demographic data, imaging data, and genotyping data. Children and their parents will been rolled over a 5-year period.

Sub-sets of patients with confirmed diagnoses of other heritable cardiovascular diseases with onset \<16 years will also be recruited.These will include children who following evaluation by their clinical multidisciplinary team (which will include a geneticist or genetic counsellor) are likely to have a rare monogenic condition. Other affected family members of eligible patients may be also invited to participate in the study.

Information for this study will be collected primarily from investigations performed as part of the participants' routine clinical care including whole genome sequencing commissioned by NHS England. The study will seek consent to access and export this data. Procedures performed as part of this study may include venepuncture and/or saliva collection and carry minimal risk to the patient.

Parents of participants that are recruited into the study will donate a blood sample (or saliva sample if unable to provide blood) and consent will be requested for collection of health information and results of relevant investigations carried out as part of their routine clinical care (e.g. an echocardiogram). Other family members that are recruited into the study will donate a blood sample (or saliva sample if unable to provide blood) and consent will be requested for collection of health information. Family members of deceased patients with cardiomyopathy or other inherited cardiac conditions may be asked if they wish to donate stored samples that may have been taken prior to death or as part of a post-mortem examination to establish cause of death. Any discussion with regard to the use of stored samples for this project will be initiated by the clinical care team for the deceased patient and their family to minimise any potential distress to the family. Sub-sets of patients may be asked to donate tissue samples taken as part of their clinical care.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Inherited Cardiac Conditions Cardiovascular Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Patients with inherited cardiac condition, onset <16 years old and Parents

Patients with a confirmed diagnosis of an inherited cardiac condition, onset \<16 years old and Parents will have samples that undergo whole genome sequencing and biomarker analysis

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Males or females with a confirmed diagnosis of childhood onset (\<16 years) PCM
* Males or females with childhood onset (\<16 years) of a rare inherited cardiac condition likely to be a monogenic condition
* Capacity for parents to provide informed consent
* Genotype negative following local standard diagnostic ICC gene panel
* Family members of patients with ICC, both affected and unaffected

Exclusion Criteria

* Parents who lack capacity to provide consent on behalf of their children/themselves
* Onset over 16 years
* Significant teratogen exposure (including maternal diabetes) likely to contribute to cardiac dysfunction (following discussion with Cardiologist)
* Significant coronary heart disease likely to contribute to cardiac dysfunction (following discussion with Cardiologist)
* Other secondary causes of cardiac dysfunction likely to explain the phenotype of the patient
* Patients with a confirmed genetic diagnosis (patients with variants of uncertain significance are not excluded).

Eligible Sex

ALL

Accepts Healthy Volunteers

No